Drug Trial Radar · NCT02294396
Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.
Last checked: Nov 20, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
649
Actual
Start
Oct 28, 2014
Primary completion
Sep 7, 2016
Study completion Sep 7, 2016
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Nov 19, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study was to evaluate the safety and efficacy of add-on therapy with anticholinergics in patients with OAB on mirabegron.
Conditions
- Overactive Bladder (OAB)
Interventions
Mirabegron tabletDrug
orally administered at a dose of 1 tablet once daily after breakfast
Solifenacin tabletDrug
orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 2 tablets)
Propiverine tabletDrug
orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 1 tablet twice daily after breakfast and after dinner)
Imidafenacin tabletDrug
orally administered at a dose of 1 tablet (0.1 mg tablet) twice daily after breakfast and after dinner (could be increased to 2 tablets twice daily after breakfast and after dinner)
Tolterodine capsuleDrug
orally administered at a dose of 1 capsule once daily after breakfast (could not be increased)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug up to week 52
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Chūbu, Japan
Site not named
Chugoku, Japan
Site not named
Hokkaido, Japan
Site not named
Kansai, Japan
Site not named
Kantou, Japan
Site not named
Kyushu, Japan
Site not named
Tōhoku, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.